First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)-FIELT study group.

被引：2
|
作者：
De Greve, J.
Van Meerbeeck, J. P.
Vansteenkiste, J. F.
Teugels, E.
Geers, C.
Meert, A.
Vuylsteke, P.
Focan, C. N. J.
Canon, J.
Humblet, Y.
Berchem, G. J.
Colinet, B.
Galdermans, D.
Bosquee, L.
Dooms, C. A.
Decoster, L.
Vermeij, J.
Dewaele, A.
Schallier, D. C. C.
机构：
[1] Univ Ziekenhuis Brussels, Brussels, Belgium
[2] Ghent Univ Hosp, Ghent, Belgium
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] UZ Brussel, Brussels, Belgium
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Clin & Maternite Sante Elisabeth, Namur, Belgium
[7] CHC Clin St Joseph, Liege, Belgium
[8] Grand Hop Charleroi, Charleroi, Belgium
[9] Catholic Univ Louvain, Ctr Canc, B-1200 Brussels, Belgium
[10] Ctr Hospier Luxembourg, Luxembourg, Luxembourg
[11] AZ Middelheim Hosp, Antwerp, Belgium
[12] CHU Sart Tilman, Dept Resp Med, B-4000 Liege, Belgium
[13] Univ Hosp Leuven, Leuven, Belgium
[14] Univ Ziekenhuis Brussels, Dept Med Oncol, Oncol Ctr, Brussels, Belgium
[15] ZNA Campus Jan Palfijn Middelheim, Merksem, Belgium
[16] Univ Ziekenhuis Brussels, Jette, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7597
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
    De Gresve, Jacques
    Van Meerbeeck, Jan
    Vansteenkiste, Johan F.
    Decoster, Lore
    Meert, Anne-Pascale
    Vuylsteke, Peter
    Focan, Christian
    Canon, Jean-Luc
    Humblet, Yves
    Berchem, Guy
    Colinet, Benoit
    Galdermans, Danny
    Bosquee, Lionel
    Vermeij, Joanna
    Dewaele, Alex
    Geers, Caroline
    Schallier, Denis
    Teugels, Erik
    PLOS ONE, 2016, 11 (03):
  • [2] FIRST-LINE ERLOTINIB IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION: A MULTICENTRE ACADEMIC PHASE II STUDY IN BELGIUM
    De Greve, Jacques
    Van Meerbeeck, Jan P.
    Vansteenkiste, Johan
    Teugels, Erik
    Geers, Caroline
    Meert, Anne-Pascale
    Vuylsteke, Peter
    Focan, Christian
    Canon, Jean-Luc
    Humblet, Yves
    Berchem, Guy J.
    Colinet, Benoit
    Galdermans, Daniella
    Bosquee, Lionel
    Dooms, Christophe
    Decoster, Lore
    Vermeij, Joanna
    Dewaele, Alex
    Schallier, Denis
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1270 - S1270
  • [3] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [4] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
  • [5] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [7] First-Line Erlotinib vs Gemcitabine/Carboplatin (GC) in Activating EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Efficacy and Safety Results from Phase III OPTIMAL Study in Chinese Patients (pts)
    Wang, Chang-Li
    Zhou, Caicun
    Wo, Yi-Long
    Lu, Shun
    Zhang, Li
    Zhang, Yiping
    Ye, Ming
    Ma, Jun
    Huang, Jianan
    Xiu, Quingyu
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S373 - S374
  • [8] Additional Biomarker Analyses from the Phase III OPTIMAL Study of First-Line Erlotinib versus Gemcitabine/Carboplatin (GC) in Chinese Patients (pts) with Advanced Activating EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
    Feng, Jifeng
    Wu, Yi-Long
    Zhou, Caicun
    Lu, Shun
    Zhang, Li
    Zhi, Xiuyi
    Cheng, Ying
    Chen, Lei
    Luo, Yi
    Hu, Chunhong
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S395 - S395
  • [9] OPTIMAL: Phase III Study of First-line Erlotinib Versus Gemcitabine Plus Carboplatin (GC) in Chinese Patients (pts) With Activating EGFR Mutation-Positive Advanced Non-small Cell Lung Cancer (NSCLC). On behalf of the OPTIMAL Investigators
    Wang, J.
    Zhou, C.
    Wu, Y.
    Lu, S.
    Zhang, L.
    Zhang, Y.
    Ye, M.
    Ma, J.
    Huang, J.
    Xiu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S507 - S508
  • [10] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
12345